Page 8 of 26, showing 50 records out of 1263 total, starting on record 351, ending on 400
| Publication |
Category |
Year |
|
358. Berger, L., El-Alfy, M., Martel, C., Labrie, F. (2005) Effects of DHEA, Premarin and Acolbifene on histomorphology and sex steroid receptors of the rat vagina. J Steroid Biochem Mol Biol, 96: 201-15. |
All publications |
2005 |
|
359. Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., El Alfy, M. (2000) Intracrinology and the skin. Horm. Res., 54: 218-229. |
All publications |
2000 |
|
360. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. |
All publications |
2000 |
|
362. Durocher, F., Simard, J., Ouellette, J., Richard, V., Labrie, F., Pelletier, G. (1997) Localization of the BRCA1 gene expression in adult cynomolgus monkey tissues. J. Histochem. Cytochem., 45: 1173-1188. |
All publications |
1997 |
|
363. Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Labrie, F. (1996) Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J. Endocrinol., 150 Suppl.: S43-S50. |
All publications |
1996 |
|
364. Sugimoto, Y., Lopez-Solache, I., Labrie, F., Luu-The, V. (1995) Cations inhibit specifically Type I 5alpha-reductase found in human skin. J. Invest. Dermatol., 104: 775-778. |
All publications |
1995 |
|
365. Couët, J., Martel, C., Labrie, Y., Luo, S., Simard, J., Labrie, F. (1994) Opposite effects of prolactin and corticosterone on the expression and activity of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase in rat skin. J. Invest. Dermatol., 103: 60-64. |
All publications |
1994 |
|
366. Luu-The, V., Sugimoto, Y., Puy, L., Labrie, Y., Lopez Solache, I., Singh, M., Labrie, F. (1994) Characterization, expression and immunohistochemical localization of 5alpha-reductase in human skin. J. Invest. Dermatol., 102: 221-226. |
All publications |
1994 |
|
367. Simard, J., Couet, J., Durocher, F., Labrie, Y., Sanchez, R., Breton, N., Turgeon, C., Labrie, F. (1993) Structure and tissue-specific expression of a novel member of the rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) family: the exclusive 3β-HSD gene expressed in the skin. J. Biol. Chem., 268: 19659-19668. |
All publications |
1993 |
|
368. Dumont, M., Luu-The, V., Dupont, E., Pelletier, G., Labrie, F. (1992) Characterization, expression and immunohistochemical localization of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in human skin. J. Invest. Dermatol., 99: 415-421. |
All publications |
1992 |
|
369. Dupont, A., Kastin, A.J., Labrie, F., Pelletier, G., Puviani, R., Schally, A.V. (1975) Distribution of radioactivity in the organs of the rat and mouse after injection of (125I)alpha-melanocyte-stimulating hormone. J. Endocrinol., 64: 237-241. |
All publications |
1975 |
|
370. Dupont, A., Labrie, F., Pelletier, G., Puviani, R., Coy, D.H., Schally, A.V., Kastin, A.V. (1975) Distribution of radioactivity in the organs of the rat and mouse after injection of L-(3H)prolyl-L-leucyl-glycinamide. J. Endocrinol., 64: 243-248. |
All publications |
1975 |
|
371. Dupont, A., Labrie, F., Pelletier, G., Puviani, R., Coy, D.H., Coy, E.J., Schally, A.V. (1974) Organ distribution of radioactivity and disappearance of radioactivity from plasma after administration of [3H]luteinizing hormone-releasing hormone to mice and rats. Neuroendocrinology, 16: 65-73. |
All publications |
1974 |
|
372. Dupont, A., Labrie, F., Pelletier, G., Puviani, R. (1972) Organ distribution of thyrotropin-releasing hormone. Gen. Comp. Endocrinol., 19: 522-526. |
All publications |
1972 |
|
373. Berger, L., El-Alfy, M., Labrie, F. (2008) Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol, 109: 67-80. |
All publications |
2008 |
|
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. |
All publications |
2008 |
|
376. Pelletier, G., Labrie, C., Martel, C., Labrie, F. (2008) Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol, 108: 102-108. |
All publications |
2008 |
|
379. Liu, H., Zheng, S.F., Bellemare, V., Pelletier, G., Labrie, F., Luu-The, V. (2007) Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem, 8: 2 |
All publications |
2007 |
|
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. |
All publications |
2006 |
|
382. Liby, K., Rendi, M., Suh, N., Royce, D.B., Risingsong, R., Williams, C.R., Lamph, W., Labrie, F., Krajewsi, S., Xu, X., Kim, H., Brown, P., Sporn, M.B. (2006) The Combination of the Rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, Synergize in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor Negative Model of Breast Cancer. Clin Cancer Res, 12: 5902-5909. |
All publications |
2006 |
|
383. Luu-The, V., Tremblay, P., Labrie, F. (2006) Characterization of type 12 17beta-hydroxysteroid dehydrogenase (17beta-HSD12), an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Molecular Endocrinology (Baltimore, Md.), 20: 437-43. |
All publications |
2006 |
|
384. Song, D., Liu, G., Luu-The, V., Zhao, D., Wang, L., Zhang, H., Xueling, G., Li, S., Desy, L., Labrie, F., Pelletier, G. (2006) Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol, 101: 136-44. |
All publications |
2006 |
|
385. Tchédam Ngatcha, B., Luu-The, V., Labrie, F., Poirier, D. (2005) Androsterone 3beta-Ether-3beta-Substituted and Androsterone 3beta-Substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J. Med. Chem., 48: 5257-5268. |
All publications |
2005 |
|
386. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. |
All publications |
2004 |
|
387. Dimitrakakis, C., Zhou, J., Wang, J., Belanger, A., Labrie, F., Cheng, C., Powell, D., Bondy, C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10: 292-298. |
All publications |
2003 |
|
388. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. |
All publications |
2003 |
|
389. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. |
All publications |
2003 |
|
390. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. |
All publications |
2003 |
|
391. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews, 24 (2): 152-182. |
All publications |
2003 |
|
392. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. |
All publications |
2003 |
|
393. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. |
All publications |
2002 |
|
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
All publications |
2002 |
|
396. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. |
All publications |
2002 |
|
399. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. |
All publications |
2001 |
|
400. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. |
All publications |
2001 |
|
401. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. |
All publications |
2001 |
|
403. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. |
All publications |
2001 |
|
404. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. |
All publications |
2001 |
|
406. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. |
All publications |
2001 |
|
407. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. |
All publications |
2000 |
|
408. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. |
All publications |
2000 |
|
409. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. |
All publications |
2000 |
|
411. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. |
All publications |
2000 |
|
412. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. |
All publications |
2000 |
|
414. The BRCA1 Exon 13 Duplication Screening Group. (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet., 67: 207-212. |
All publications |
2000 |
|
416. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. |
All publications |
1999 |
|
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. |
All publications |
1999 |
|
418. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. |
All publications |
1999 |
|
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. |
All publications |
1999 |
|
421. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. |
All publications |
1999 |